Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial

Published:1986-06 Issue:2 Volume:7 Page:105-109
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Tr

Author:

Delozier Thierry,Julien Jean-Pierre,Juret Paul,Veyret Corinne,Couëtte Jean-Etienne,Graic Yvon,Ollivier Jean-Michel,de Ranieri Edith

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF01806795.pdf

Reference11 articles.

1. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Statist Assoc 53: 457–481, 1958

2. Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. New Engl J Med 305: 1–6, 1981

3. Fisher B and other NSABP investigators: Treatment of primary breast cancer with L.PAM/5-F.U. and tamoxifen: an interim report. Breast Cancer Res Treat 3 (Suppl): 7–17, 1983

4. Hubay CA, Pearson OH, Marshall JS, et al: Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer 46: 2805–2808, 1980

5. Pearson OH, Hubay CA, Marshall JS, et al: Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage II breast cancer: five-years results. Breast Cancer Res Treat 3 (Suppl): 61–68, 1983

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles;Molecules;2020-03-05

2. New piperidine derivative DTPEP acts as dual-acting anti-breast cancer agent by targeting ERα and downregulating PI3K/Akt-PKCα leading to caspase-dependent apoptosis;Cell Proliferation;2018-08-09

3. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy;Molecular and Cellular Endocrinology;2015-12

4. Adjuvant Therapy: The Breakthrough;Tamoxifen;2013

5. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;The Lancet;2011-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3